zoldonrasib
Asset
RAS(ON) G12D-selective inhibitor
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- KRAS
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Metastatic RAS G12D pancreatic adenocarcinoma
Phase 3, globenewswire.com, 5 Oct 2026
Metastatic RAS G12D pancreatic cancer
Phase 3, globenewswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.